Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 61

1.

Induction of antiviral genes by the tumor microenvironment confers resistance to virotherapy.

Liu YP, Suksanpaisan L, Steele MB, Russell SJ, Peng KW.

Sci Rep. 2013;3:2375. doi: 10.1038/srep02375.

2.

Macrophage response to oncolytic paramyxoviruses potentiates virus-mediated tumor cell killing.

Tan DQ, Zhang L, Ohba K, Ye M, Ichiyama K, Yamamoto N.

Eur J Immunol. 2016 Apr;46(4):919-28. doi: 10.1002/eji.201545915. Epub 2016 Feb 3.

3.

Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity.

Ilkow CS, Marguerie M, Batenchuk C, Mayer J, Ben Neriah D, Cousineau S, Falls T, Jennings VA, Boileau M, Bellamy D, Bastin D, de Souza CT, Alkayyal A, Zhang J, Le Boeuf F, Arulanandam R, Stubbert L, Sampath P, Thorne SH, Paramanthan P, Chatterjee A, Strieter RM, Burdick M, Addison CL, Stojdl DF, Atkins HL, Auer RC, Diallo JS, Lichty BD, Bell JC.

Nat Med. 2015 May;21(5):530-6. doi: 10.1038/nm.3848. Epub 2015 Apr 20.

PMID:
25894825
4.

Interleukin-6 and Interferon-α Signaling via JAK1-STAT Differentially Regulate Oncolytic versus Cytoprotective Antiviral States.

Danziger O, Pupko T, Bacharach E, Ehrlich M.

Front Immunol. 2018 Jan 30;9:94. doi: 10.3389/fimmu.2018.00094. eCollection 2018.

5.

Vesicular stomatitis virus has extensive oncolytic activity against human sarcomas: rare resistance is overcome by blocking interferon pathways.

Paglino JC, van den Pol AN.

J Virol. 2011 Sep;85(18):9346-58. doi: 10.1128/JVI.00723-11. Epub 2011 Jul 6.

6.

Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication.

Zhu H, Butera M, Nelson DR, Liu C.

Virol J. 2005 Sep 7;2:80.

7.

VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment.

Qiao J, Moreno J, Sanchez-Perez L, Kottke T, Thompson J, Caruso M, Diaz RM, Vile R.

Gene Ther. 2006 Oct;13(20):1457-70. Epub 2006 May 25.

PMID:
16724095
8.

Combined genetic and epigenetic interferences with interferon signaling expose prostate cancer cells to viral infection.

Danziger O, Shai B, Sabo Y, Bacharach E, Ehrlich M.

Oncotarget. 2016 Aug 9;7(32):52115-52134. doi: 10.18632/oncotarget.10313.

9.

Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy.

Saloura V, Wang LC, Fridlender ZG, Sun J, Cheng G, Kapoor V, Sterman DH, Harty RN, Okumura A, Barber GN, Vile RG, Federspiel MJ, Russell SJ, Litzky L, Albelda SM.

Hum Gene Ther. 2010 Jan;21(1):51-64. doi: 10.1089/hum.2009.088.

10.

Imaging of intratumoral inflammation during oncolytic virotherapy of tumors by 19F-magnetic resonance imaging (MRI).

Weibel S, Basse-Luesebrink TC, Hess M, Hofmann E, Seubert C, Langbein-Laugwitz J, Gentschev I, Sturm VJ, Ye Y, Kampf T, Jakob PM, Szalay AA.

PLoS One. 2013;8(2):e56317. doi: 10.1371/journal.pone.0056317. Epub 2013 Feb 18.

11.

Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus.

Diaconu I, Cerullo V, Hirvinen ML, Escutenaire S, Ugolini M, Pesonen SK, Bramante S, Parviainen S, Kanerva A, Loskog AS, Eliopoulos AG, Pesonen S, Hemminki A.

Cancer Res. 2012 May 1;72(9):2327-38. doi: 10.1158/0008-5472.CAN-11-2975. Epub 2012 Mar 6.

12.

Global transcriptional profiling demonstrates the combination of type I and type II interferon enhances antiviral and immune responses at clinically relevant doses.

Tan H, Derrick J, Hong J, Sanda C, Grosse WM, Edenberg HJ, Taylor M, Seiwert S, Blatt LM.

J Interferon Cytokine Res. 2005 Oct;25(10):632-49.

PMID:
16241862
13.

Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.

Zhang Q, Chen G, Peng L, Wang X, Yang Y, Liu C, Shi W, Su C, Wu H, Liu X, Wu M, Qian Q.

Clin Cancer Res. 2006 Nov 1;12(21):6523-31.

14.

Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies.

Ong HT, Hasegawa K, Dietz AB, Russell SJ, Peng KW.

Gene Ther. 2007 Feb;14(4):324-33. Epub 2006 Oct 19.

PMID:
17051248
15.

Role of NK cells in immunotherapy and virotherapy of solid tumors.

Cantoni C, Grauwet K, Pietra G, Parodi M, Mingari MC, Maria AD, Favoreel H, Vitale M.

Immunotherapy. 2015;7(8):861-82. doi: 10.2217/imt.15.53. Epub 2015 Aug 28. Review.

PMID:
26314197
16.

VSV virotherapy improves chemotherapy by triggering apoptosis due to proteasomal degradation of Mcl-1.

Schache P, Gürlevik E, Strüver N, Woller N, Malek N, Zender L, Manns M, Wirth T, Kühnel F, Kubicka S.

Gene Ther. 2009 Jul;16(7):849-61. doi: 10.1038/gt.2009.39. Epub 2009 Apr 16.

PMID:
19369968
17.

Treatment of chemotherapy resistant ovarian cancer with a MDR1 targeted oncolytic adenovirus.

Rein DT, Volkmer A, Beyer IM, Curiel DT, Janni W, Dragoi A, Hess AP, Maass N, Baldus SE, Bauerschmitz G, Breidenbach M.

Gynecol Oncol. 2011 Oct;123(1):138-46. doi: 10.1016/j.ygyno.2011.06.007. Epub 2011 Jul 13.

PMID:
21741695
18.
19.
20.

Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers.

Sinkovics JG, Horvath JC.

Arch Immunol Ther Exp (Warsz). 2008 Dec;56 Suppl 1:3s-59s. doi: 10.1007/s00005-008-0047-9. Epub 2008 Dec 23. Review.

PMID:
19104757

Supplemental Content

Support Center